greater emphasis should be given in rehabilitation to attempts to alter attitudes and beliefs. Structured supportive counselling, aimed at increasing confidence and reducing fear, may provide a means of considerably reducing disability.
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D B JONES, R D CARTER, B HAITAS, J I MANN Abstract
Platelet aggregation is enhanced in diabetes mellitus, and platelets may be implicated in the pathogenesis of diabetic angiopathy. Increased platelet aggregation is probably mediated by the production of the proaggregatory prostaglandin thromboxane, which is synthesised from arachidonic acid (C20:4) by the action of the platelet enzymes cyclo-oxygenase and thromboxane synthetase.
The fatty acid composition of platelet phospholipid was measured in 20 normal controls, 10 insulin-treated diabetics with no or minimal retinopathy, and 10 insulintreated diabetics with proliferative retinopathy. The percentage of arachidonic acid was significantly higher in controls (mean 22-6%) than in the diabetics with no or minimal retinopathy (mean 18 5%; p <0 025) and the diabetics with proliferative retinopathy (mean 14 6%; p <0 001). The percentage of linoleic acid was lower in controls (mean 8-9%) than in the diabetics with no or minimal retinopathy (mean 12 6%; p <0 01) and diabetics with proliferative retinopathy (mean 13 1%; p <0 001). The The reciprocal correlation between percentages of arachidonic acid and glycosylated haemoglobin suggests that diabetic control may influence thromboxane release and platelet activity directly and that low percentages of arachidonic acid reflect the increased degree of in-vivo activation.
Introduction
The control of platelet aggregation is influenced by two conflicting prostaglandins. Thromboxane A2 is synthesised and released by platelets and promotes aggregation,' while prostacyclin is produced by vascular endothelium and is antiaggregatory.2 Disturbed metabolism of either of these has been suggested as the cause of increased platelet aggregation in diabetes.3
Raised circulating concentrations of thromboxane B2 (the metabolite of thromboxane A2) have been shown in diabetics with retinopathy, though thromboxane production by platelets in vitro was low or normal. 4 We have studied the phospholipid fatty acid composition of platelets from diabetics with minimal background or severe proliferative retinopathy because arachidonic acid represents the crucial substrate for production of thromboxane A,. We also studied the relation between glycaemic control and altered composition of platelet fatty acids.
Patients and methods
We studied three groups of subjects: 20 normal controls, 10 insulin-treated diabetics with no or minimal retinopathy, and 10 insulin-treated diabetics with proliferative retinopathy. All were men and there were no significant differences in mean age (45-1, 45-6, and 45 0 years) and mean percentage ideal body weight (106%, 105 %, and 1060%). The two diabetic groups were similar with regard to mean duration of diabetes (24-2 and 25-1 years) and mean insulin dose/kg body weight (0-84 and 0 79 unit).
The diabetics were originally advised to take a low carbohydrate diet but in practice at the time of the study most were restricting only sugar. The controls received no dietary advice.
The presence and degree of retinopathy was determined by fundoscopy and retinal photography after fluorescein angiography.
Blood was taken after an overnight fast for measurement of glucose concentration, percentage of glycosylated haemoglobin (haemoglobin A,c), cholesterol (total and in the lipoprotein fractions), and total triglyceride concentrations. Citrated blood (30 ml) was used to determine phospholipid fatty acid composition. Platelet-rich plasma was prepared by centrifugation at 180 g for 10 minutes. This was washed twice in 099% sodium chloride and centrifuged at 500 g after each washing to obtain a platelet pellet. The lipid fraction was extracted using a 2:1 chloroform :methanol solvent. Thin-layer chromatography in one dimension using a hexane, diethyl ether, and acetic acid mixture was then performed on an activated silica gel plate to obtain the phospholipid fraction with development in iodine vapour. The phospholipid was then removed and gas-liquid chromatography carried out on methylated aliquots.5 The percentage of each fatty acid was then calculated by triangulation from the chromatogram obtained.
Glucose significantly lower in the diabetic proliferative retinopathy group (14-6±5-3%; p<0.001). The difference between the two diabetic groups was not statistically significant (p < 0-1) (fig 1) . Linoleic acid (C18:2)-The percentage of linoleic acid was higher in both the diabetic proliferative retinopathy group (13-1±3-5%; p <0-001) and the diabetic minimal retinopathy group (12-6 ±5-0%; p < 0-01) than in the controls (8-9 ±2 3%). The difference between the two diabetic groups was not statistically significant.
Linolenic acid (C18:3)-The percentage of linolenic acid was significantly lower in the proliferative retinopathy group (2-7±1-7%) than in the normal controls (4-4 ± 1-2%; p < 0-01).
There was no difference statistically between the three groups for the ratio of arachidonic acid to eicosapentanoic acid (C20 :4, C20:5).
The two diabetic groups were similar for all biochemical variables except the percentage of glycosylated haemoglobin, which was higher in the proliferative retinopathy group (p < 0-025).
Correlation of platelet fatty acids and glycaemic control-Significant correlations were present for the percentage of arachidonic acid against the percentage of glycosylated haemoglobin (Rs= -0-58; p < 0-001) (see fig 2) and also for the percentage of linoleic acid and glycosylated haemoglobin (Rs = 0-51; p <0-01) for the total cohort. When the groups were separated the diabetics showed a significant negative correlation between arachidonic acid and the percentage of glycosylated haemoglobin (Rs = -0-54; p <0-01) but no correlation between linoleic or linolenic acid and glycosylated haemoglobin. In the normal control group no significant correlations were seen between the percentage of glycosylated haemoglobin and arachidonic acid (R = 0-14) or linoleic acid (R = 0-2) but a significant negative correlation was seen with linolenic acid (R = -0-57; p <0-02). There were no I w w w | l l l~~~~~~~~~~~~~~~~~~~~~~~~~~~õ f significant correlations present for platelet fatty acid composition and fasting concentrations of plasma glucose or cholesterol, lipoproteins, and total triglycerides. Trend test-There was no statistically significant trend in either arachidonic acid or linoleic acid according to retinopathy groups.
Discussion
Abnormal platelet aggregation has been well described in diabetes mellitus, but the mechanism of this disturbed function and its relation to blood glucose control and to diabetic complications are less well understood." 13 We have shown that platelets from diabetics have a lower percentage of arachidonic acid in the phospholipid fraction than platelets of normal subjects. The correlation between the percentage of arachidonic acid and the percentage of glycosylated haemoglobin implies a link between long-term blood glucose control and the biosynthetic pathway of thromboxane in platelets. The fasting blood glucose concentration in normal and diabetic subjects did not correlate with the percentage of arachidonic acid, suggesting that medium and long-term fluctuations in glucose control but not acute changes affect metabolism.
There was no significant difference in percentage of arachidonic acid between the two retinopathy groups, though both differed significantly from normal. The lower mean value in the proliferative retinopathy group was a reflection of poorer glycaemic control in that group. Our results suggest that vascular disease by itself may not influence platelet metabolism.
We could not confirm the report by Kalofoutis and Lekakis14 that the percentage of arachidonic acid in diabetic platelets is higher than normal. Their analytical methods were apparently similar to ours and are unlikely to explain the discrepancy. Patient selection, in particular duration of diabetes and body weight, may account for some of the difference but dietary factors were probably more important. Evidence is rapidly accumulating on how diet affects platelet fatty acids.'5-17 Some dietary regimens may have an adverse effect on platelet behaviour by altering the amount of proaggregatory prostaglandin precursors available for thromboxane synthesis. Experimental support for this hypothesis includes the reduction of platelet aggregation by supplementation with eicosapentanoic acid"8 in normal subjects and also data from studies in Eskimos,"9 which show changes in platelet structure and aggregation related to high polyunsaturated fat intake. Differences may exist in the kinetics of the arachidonic pathway between populations.
Linoleic acid may play an indirect part in the balance of platelet aggregation. Studies have shown reduced platelet aggregation in subjects fed linoleic acid supplements20 and increased platelet aggregation in subjects fed arachidonic acid. 16 Arachidonic acid occurs in only small amounts in food and it has long been thought that conversion from linoleic acid takes place. Our results show that diabetics have more linoleic acid in their platelets than normal subjects, which contrasts with the increased platelet aggregation seen in diabetics. Possibly diabetics have an inability to convert linoleic acid to arachidonic acid which in some way contributes to the platelet instability and which correlates with glycaemic control. The percentage of linolenic acid was significantly lower in the diabetics with proliferative retinopathy than in the normal controls but no difference occurred between the minimal retinopathy group and the controls. Linolenic acid undergoes conversion to eicosapentanoic acid and subsequently to analogues of thromboxane which show reduced biological activity. The low percentages of linolenic acid may further contribute to imbalance in an equilibrium of thromboxane analogues. The proportion of eicosapentanoic acid itself, however, was not significantly different among the three groups.
Other workers have suggested that the ratio of arachidonic acid to eicosapentanoic acid is important in platelet aggregation'7 18 but we observed no differences ifn this ratio between our normal controls and the two diabetic groups.
We believe that our results help to explain previous data on thromboxane production in diabetes. Though circulating concentrations of thromboxane B2 are raised in diabetes, in-vitro thromboxane production by platelets is reduced.4 When arachidonic acid is added to platelets in low concentrations thromboxane production is increased.21 Both these findings are compatible with reduced amounts of endogenous platelet arachidonic acid.
